September 29, 2022
4D pharma will not report it’s half year interim results
4D pharma will not report its interim results for the 6 months to 30 June 2022 by 30 September as…
Pharmaceuticals, Biotechnology and Life Sciences
Category: Europe
June 14, 2022
ProBiotix Health with new CEO
ProBiotix Health, a life sciences company developing clinically proven probiotic solutions to tackle chronic lifestyle diseases like high cholesterol, high blood pressure and atherosclerosis, has appointed Steen Andersen as Chief Executive Officer.
June 14, 2022
FDA lifts clinical hold on Homology Medicines’ pheNIX trial
The U.S. Food and Drug Administration (FDA) has notified Homology that the clinical hold on its pheNIX gene therapy trial of HMI-102 in adults with phenylketonuria (PKU) has been lifted.
June 3, 2022
Novartis’ Kisqali the only CDK4/6 inhibitor consistent significant overall survival across entire Phase III program
Novartis today announced new overall survival (OS) and quality of life (QoL) analyses which evaluated Kisqali® (ribociclib) plus endocrine therapy for patients with hormone receptor-positive/human epidermal growth factor receptor-negative (HR+/HER2-) advanced or metastatic breast cancer. These data will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, Novartis said.
April 28, 2022
Vifor-Cara Therapeutics’s Kapruvia Approved for Treatment of Moderate-to-Severe Pruritus in Hemodialysis in EU
Vifor Fresenius Medical Care Renal Pharma and Cara Therapeutics have announced that the European Commission has granted marketing authorization to Kapruvia (difelikefalin) for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adult hemodialysis patients.
April 28, 2022
Novartis Announces Positive Phase III Results for its ESCC Drug
Novartis has announced positive topline results from an interim analysis of the Phase III RATIONALE 306 study, which showed anti-PD-1 immune checkpoint inhibitor tislelizumab plus chemotherapy significantly improved overall survival (OS) compared to chemotherapy in patients with previously untreated unresectable, locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC), regardless of PD-L1 expression.
April 27, 2022
Basilea announces licensing of a novel first-in-class antifungal program from Fox Chase Chemical Diversity Center
Basilea Pharmaceutica Ltd has entered into a licensing agreement with the U.S.-based company, Fox Chase Chemical Diversity Center, Inc. (FCCDC), for a preclinical program on novel first-in-class broad spectrum antifungals with activity against difficult-to-treat mold infections.
April 26, 2022
ViGeneron and Daiichi Sankyo to Develop a Novel Gene Therapy for Prevalent Eye Diseases
ViGeneron GmbH, a next-generation gene therapy company, has announced a follow-on collaboration with Daiichi Sankyo Company, Limited to utilize ViGeneron’s novel engineered recombinant adeno-associated virus vectors (vgAAVs) to address an undisclosed target for the treatment of prevalent eye diseases.
April 26, 2022
Aperion Biologics create invIOs Holding through demerger
APEIRON Biologics AG has announced that the annual general meeting held yesterday has approved the new structure of the group…
April 26, 2022
Valneva and Pfizer Report Positive Phase 2 Pediatric Data for Lyme Disease Vaccine Candidate
Valneva SE and Pfizer Inc. have reported positive Phase 2 pediatric data for their Lyme disease vaccine candidate, VLA15.